Antiviral Therapy · 2005 · 40 citations · 72 references
Life SciencesPharmacokineticsPharmacologyInfectious Disease PharmacotherapyMolecular VirologyVirologyAntiretroviral TherapyAntiviral Drug ResistanceAntiviral PharmacologyAntiviral PharmacotherapyAntiviral ResistanceAntiviral TherapyAntiretroviral ResponseAntiviral Resistance MutationsDrug Trough ConcentrationHiv Antiretroviral TherapyProtease Inhibitor ResistanceProtease InhibitorsResistance-associated MutationsViral Protease Inhibition
A systemic review is presented of all studies that have evaluated the inhibitory quotient (IQ). The IQ is defined as the ratio between (trough) drug concentration and level of drug resistance of the HIV isolate. From the studies presented, it can be concluded that for protease inhibitors (PIs) and efavirenz, the phenotypic IQ is associated with virological response. The genotypic IQ (GIQ) for PIs was also demonstrated to be associated with virological response. An intrinsic limitation of the GIQ is that it is only applicable for PIs, of which resistance is based on the cumulative effect of mutations. As the IQ can be modified by adjustment of the drug dosage, it may be of clinical value. Its application in patient care should therefore be further investigated.
72
Changing patterns of mortality across Europe in patients infected with HIV-1
Amanda Mocroft, Stefano Vella, Antonio Chiesi et al. · The Lancet · 1998 · 1.3K citations
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Akhteruzzaman Molla, Marina Korneyeva, Qing Gao et al. · Nature Medicine · 1996 · 768 citations